Cecilie Amalie Brøgger Svane

Cecilie Amalie Brøgger Svane

Auto-generated profile, based on publicly available information

Cecilie Amalie Brøgger Svane

Department of Translational and Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2025 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
KHKristine Henriksen
Kristine Henriksen
AJAnne Jørgensen
Anne Jørgensen
Simranjeet KaurSimranjeet Kaur
Simranjeet Kaur
RGRebekka Gerwig
Rebekka Gerwig
CSCecilie Amalie Brøgger Svane
Cecilie Amalie Brøgger Svane
Joachim StorlingJoachim Storling
Joachim Storling
Immune-mediated beta-cell destruction and lack of alpha-cell responsiveness to hypoglycaemia are hallmarks of type 1 diabetes pathology. The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may hold therapeutic potential for type 1 diabetes due to its insulinotropic and glucagonotropic effects, as well as its cytoprotective effects shown in rodent beta cells. To further increase our understanding of GIP's effects on human beta cells, we here examined the functional, protective, and transcriptomic effects of GIP in human EndoC-βH5 beta cells and isolated human islets in the presence or absence of proinflammatory cytokines (interferon (IFN)-γ ± interleukin (IL)-1β) as a mimic of type 1 diabetes. GIP dose-dependently augmented glucose-stimulated insulin secretion from EndoC-βH5 cells and increased insulin and glucagon secretion from human islets at high and low glucose concentrations, respectively. The insulinotropic effect of GIP in EndoC-βH5 cells was abrogated by KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase 2 (CaMK2). GIP did not prevent cytokine-induced apoptosis in EndoC-βH5 cells or human islets, and GIP did not protect against cytokine-induced functional impairment in EndoC-βH5 cells. GIP treatment of human islets for 24 h had no effects on the transcriptome and did not modulate cytokine-induced transcriptional changes. However, GIP augmented IL-1β + IFNγ-induced secretion of interleukin (IL)-10 and c-c motif chemokine ligand (CCL)-2 from human islets while decreasing the secretion of c-x-c motif chemokine ligand (CXCL)-8. In EndoC-βH5 cells, GIP reduced IFN-γ-induced secretion of tumor necrosis factor (TNF)-α, IL-2, IL-6, and IL-10 but increased the secretion of CXCL8, CCL2, CCL4, and CCL11. In conclusion, our results suggest that the insulinotropic effect of GIP is CaMK2-dependent. Furthermore, our findings indicate that GIP neither exerts cytoprotective effects against cytokines nor modulate the transcriptome of human islets. GIP may, however, exert selective modulatory effects on secreted inflammatory factors from cytokine-exposed beta cells and islets.

13 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CFCaroline Frørup
Caroline Frørup
CSCecilie A.B. Svane
Cecilie A.B. Svane
MJMathias Høj Jensen
Mathias Høj Jensen
LHLaurits J. Holm
Laurits J. Holm
KPKristina Pedersen
Kristina Pedersen
TFTina Fløyel
Tina Fløyel
There is an emerging role for the lysosomal protease cathepsin S (CTSS) in the pathogenesis of type 1 diabetes (T1D). This is supported by key findings, including that circulating levels of CTSS are increased in individuals with T1D, and that genetic ablation of Ctss in non-obese diabetic (NOD) mice - a well-established model of autoimmune diabetes - reduces both insulitis and diabetes incidence. In this study, we evaluated the impact of the pharmacological Ctss inhibitor LY3000328 on diabetes development in NOD mice. Female NOD mice were fed a standard diet with or without LY3000328 (10 mg/kg/day) from three weeks of age. The effect of treatment on diabetes incidence, insulitis, glucose tolerance, and circulating inflammatory markers was assessed. Furthermore, the spatial insulin and Ctss protein expressions were investigated in pancreatic islets from pre-diabetic and diabetic NOD mice fed diet with or without LY3000328. Finally, cathepsin B and L protein levels were quantified in both spleen and pancreas lysates. Compared to NOD mice on control diet, NOD mice on the LY3000328 diet had accelerated diabetes incidence, impaired glucose tolerance, and tended to have more insulitis. Moreover, 13-week-old NOD mice from the LY3000328 group had a reduced insulin-positive area within the islets, an increased Ctss-positive area within the islet infiltrate, and elevated pancreatic cathepsin B and L levels. Our study shows that LY3000328 accelerates diabetes development in NOD mice. The data highlight the multifaceted involvement of Ctss in T1D pathogenesis and emphasize the complexity of targeting Ctss as a therapeutic strategy.

29 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CFCaroline Frørup
Caroline Frørup
RGRebekka Gerwig
Rebekka Gerwig
CSCecilie Amalie Søndergaard Svane
Cecilie Amalie Søndergaard Svane
JMJoana Mendes Lopes de Melo
Joana Mendes Lopes de Melo
TFTina Fløyel
Tina Fløyel
Joachim StorlingJoachim Storling
Joachim Storling
Objective: EndoC-βH5 is a newly established human beta-cell model which may be superior to previous models of native human beta cells. Exposure of beta cells to proinflammatory cytokines is a widely used in vitro model of immune-mediated beta-cell failure in type 1 diabetes and we therefore performed an in-depth characterisation of the effects of cytokines on EndoC-βH5 cells. Methods: The sensitivity profile of EndoC-βH5 cells to the toxic effects of the pro-inflammatory cytokines interleukin-1β (IL-1β), interferon γ (IFNγ) and tumour necrosis factor-α (TNFα) was examined in titration and time-course experiments. Cell death was evaluated by caspase 3/7 activity, cytotoxicity, viability, TUNEL assay and immunoblotting. Mitochondrial function was evaluated by extracellular flux technology. Activation of signalling pathways and major histocompatibility complex (MHC) class I expression were examined by immunoblotting, immunofluorescence, and real-time quantitative PCR (qPCR). Glucose-stimulated insulin secretion (GSIS) and cytokine-induced chemokine secretion were measured by ELISA and Meso Scale Discovery multiplexing electrochemiluminescence, respectively. Global gene expression was characterised by stranded RNA sequencing. Results: Cytokines increased caspase activity and cytotoxicity in EndoC-βH5 cells in a time- and dose-dependent manner. The proapoptotic effect of cytokines was primarily driven by IFNγ. Cytokine exposure caused impaired mitochondrial function, diminished GSIS, and induced secretion of chemokines. At the signalling level, cytokines increased the phosphorylation of signal transducer and activator of transcription 1 (STAT1) but not c-jun N-terminal kinase (JNK) and did not cause degradation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor α (IκBα). MHC class I was induced by cytokines. Cytokine exposure caused significant changes to the EndoC-βH5 transcriptome including upregulation of HLA genes, endoplasmic reticulum stress markers, and non-coding RNAs. Among the differentially expressed genes were several type 1 diabetes risk genes. Conclusions: Our study provides detailed insight into the functional and transcriptomic effects of cytokines on EndoC-βH5 cells. This knowledge will be helpful for future investigations studying cytokine effects in this cell model.

3 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CSCecilie Amalie Brøgger Svane
Cecilie Amalie Brøgger Svane
AMAdam Boegh Marstrand-Joergensen
Adam Boegh Marstrand-Joergensen
AJAnne Joergensen
Anne Joergensen
RGRebekka Hanne Gerwig
Rebekka Hanne Gerwig
JGJosefine Gudmann
Josefine Gudmann
Joachim StorlingJoachim Storling
Joachim Storling
Background: Inflammation-induced pancreatic islet-cell death and dysfunction are key aspects of both type 1 and type 2 diabetes. Stem cell-derived islets (SC-islets) are an emerging tool in diabetes research, however, our understanding of how inflammation affects SC-islet function is incomplete. We therefore aimed to thoroughly characterize how SC-islets respond to pro-inflammatory cytokines at the functional and transcriptomic levels in comparison with human primary islets and EndoC-βH5 cells. Method: A 7-stage differentiation protocol was used to generate SC-islets with insulin-, glucagon-, and somatostatin-positive cells. SC-islets, primary human islets and EndoC-βH5 cells were exposed to different doses of pro-inflammatory cytokines (IL-1β + IFNγ + TNFα) including a high dose for up to 48 h and a low dose up to 144 h to mimic the intense islet inflammation in T1D and chronic low-grade inflammation in T2D, respectively. Differential gene expression (RNA-seq), cell death, activation of key signalling proteins, hormones, and chemokine secretion were determined. Results: Basal expression of key islet-cell identity genes in SC-islets correlated well with that of primary islets and EndoC-βH5 cells. In SC islets, cytokines dose-dependently induced activation of key proximal signalling pathways (NFκB, STAT1, and JNK), upregulation of major histocompatibility complex (MHC) class I, and increased cell death (cytotoxicity and caspase 3/7 activity). In head-to-head experiments, SC-islets displayed similar cytokine responses particularly as primary islets regarding induction of cell death, chemokine secretion, differential gene expression, and protein levels of cell death executioners (gasdermin D and caspase-7). Cytokines increased insulin release in SC-islets and primary islets, while diminishing insulin secretion in EndoC-βH5 cells. Cytokines reduced glucagon release in SC-islets, which was partially restored by treatment with the incretin hormone glucose-dependent insulinotropic peptide (GIP) with or without a glucagon-like peptide 1 (GLP-1) receptor agonist (liraglutide). Conclusion: SC-islets are highly responsive to inflammation with a high degree of similarity to primary islets. Our results support the use of SC-islets as a valid tool in inflammation and diabetes research.

18 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KHKristine Henriksen
Kristine Henriksen
AJAnne Jørgensen
Anne Jørgensen
Simranjeet KaurSimranjeet Kaur
Simranjeet Kaur
RGRebekka Gerwig
Rebekka Gerwig
CSCecilie Amalie Brøgger Svane
Cecilie Amalie Brøgger Svane
Joachim StorlingJoachim Storling
Joachim Storling
Immune-mediated beta-cell destruction and lack of alpha-cell responsiveness to hypoglycaemia are hallmarks of type 1 diabetes pathology. The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may hold therapeutic potential for type 1 diabetes due to its insulinotropic and glucagonotropic effects, as well as its beta-cell protective effects shown in rodent islets. Here, we examined the functional, protective, and transcriptomic effects of GIP treatment upon diabetogenic cytokine exposure to interleukin (IL)-1β ± interferon (IFN)-γ in human EndoC-βH5 beta cells and isolated human islets, respectively. GIP dose-dependently augmented glucose-stimulated insulin secretion from EndoC-βH5 cells and increased insulin and glucagon secretion from human islets during high and low glucose concentrations, respectively. The insulinotropic effect of GIP in EndoC-βH5 cells was abrogated by KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase 2 (CaMK2). GIP did not prevent cytokine-induced apoptosis or cytokine-induced functional impairment of human EndoC-βH5 cells. GIP also did not prevent cytokine-induced apoptosis in human islets. GIP treatment of human islets with or without cytokines for 24 hours did not significantly impact the transcriptome. GIP potentiated cytokine-induced secretion of IL-10 and c-c motif chemokine ligand (CCL)-2 from human islets while decreasing the secretion of c-x-c motif chemokine ligand (CXCL)-8. In EndoC-βH5 cells, GIP reduced IFN-γ-induced secretion of tumor necrosis factor (TNF)-α, IL-2, IL-6, and IL-10 but increased the secretion of CXCL8, CCL2, CCL4, and CCL11. In conclusion, our results suggest that the insulinotropic effect of GIP is CaMK2-dependent. Furthermore, our results indicate that GIP does not provide substantial cytoprotective effects against diabetogenic cytokine challenge or significantly modulate the transcriptome of human islets when applied at a supraphysiological level. GIP may, however, still exert selective inflammation-modulatory effects upon diabetogenic cytokine exposure.